Page last updated: 2024-12-11

r 121919

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9821250
CHEMBL ID309138
SCHEMBL ID5600844
MeSH IDM0368498

Synonyms (35)

Synonym
r-121919
nbi 30775
r121919
r 121919
3-(6-dimethylamino-4-methylpyridin-3-yl)-2,5-dimethyl-n,n-dipropylpyrazolo[5,1-b]pyrimidin-7-amine
gtpl3520
[3-(6-dimethylamino-4-methyl-pyridin-3-yl)-2,5-dimethyl-pyrazolo[1,5-a]pyrimidin-7-yl]-dipropyl-amine
bdbm50116105
3-(6-(dimethylamino)-4-methylpyridin-3-yl)-2,5-dimethyl-n,n-dipropylpyrazolo[1,5-a]pyrimidin-7-amine
[3-(6-dimethylamino-4-methyl-pyridin-3-yl)-2,5-dimethyl-4h-pyrazolo[1,5-a]pyrimidin-7-yl]-dipropyl-amine
CHEMBL309138 ,
195055-03-9
AKOS016002213
unii-g82n555u1n
nbi-30775
pyrazolo(1,5-a)pyrimidin-7-amine, 3-(6-(dimethylamino)-4-methyl-3-pyridinyl)-2,5-dimethyl-n,n-dipropyl-
g82n555u1n ,
AB21702
SCHEMBL5600844
3-[6-(dimethylamino)-4-methyl-3-pyridinyl]-2,5-dimethyl-n,n-dipropylpyrazolo[2,3-a]-pyrimidin-7-amine
ANNRUWYFVIGKHA-UHFFFAOYSA-N ,
3-[6-(dimethylamino)-4-methylpyridin-3-yl]-2,5-dimethyl-n,n-dipropylpyrazolo[1,5-a]pyrimidin-7-amine
DTXSID00173162
r-121,919
3-[6-(dimethylamino)-4-methyl-pyrid-3-yl]-2,5-dimethyl-n,n-dipropyl-pyrazolo[2,3-a]pyrimidin-7-amine
CS-6231
HY-14127
FT-0767007
BCP23964
r121919;r 121919;r-121919;nbi30775
Q27088503
nbi30775
HMS3746O07
MS-26233
A925135

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" In particular, there were no adverse effects or impairment of the hypothalamic-pituitary-gonadal system, the hypothalamic-pituitary-thyroid axis, the renin-angiotensin system, prolactin or vasopressin secretion."( Treatment of depression with the CRH-1-receptor antagonist R121919: endocrine changes and side effects.
Ackl, N; Holsboer, F; Ising, M; Künzel, HE; Nickel, T; Sonntag, A; Uhr, M; Zobel, AW,
)
0.13

Bioavailability

ExcerptReferenceRelevance
" These findings led to a clinical development program exploring the antidepressive potential of R121919, a water-soluble pyrrolopyrimidine that binds with high affinity to human CRH(1) receptors and is well absorbed in humans."( Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated.
Ackl, N; Holsboer, F; Ising, M; Künzel, HE; Nickel, T; Sonntag, A; Zobel, AW,
)
0.13
" Pharmacokinetic studies in rats showed that 26 h was orally bioavailable and able to penetrate into the brain."( Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Bozigian, H; Chen, C; Chen, TK; Grigoriadis, DE; Huang, CQ; Liu, XJ; McCarthy, JR; Saunders, J; Webb, TR; Wilcoxen, KM; Xie, YF; Zhu, YF, 2004
)
0.32

Dosage Studied

ExcerptRelevanceReference
"NBI30775 reduces levels of anxiety in mice (under basal conditions) with a steep dose-response curve."( Identification of molecules potentially involved in mediating the in vivo actions of the corticotropin-releasing hormone receptor 1 antagonist, NBI30775 (R121919).
Almeida, OF; Binder, E; Binder, EB; Holsboer, F; Ohl, F; Post, A; Rücker, M; Sillaber, I; Welt, S, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Corticotropin-releasing factor receptor 1Homo sapiens (human)IC50 (µMol)0.03210.00070.06490.3400AID1293579; AID1435127; AID1435128; AID242269; AID248932; AID346894; AID705772
Corticotropin-releasing factor receptor 1Homo sapiens (human)Ki0.00520.00080.01020.2400AID1253854; AID1253856; AID239431; AID239538; AID362068; AID538004; AID53978; AID609182; AID622045; AID683206
Corticotropin-releasing factor receptor 1Rattus norvegicus (Norway rat)Ki0.00440.00100.00290.0050AID53978; AID608155
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Corticotropin-releasing factor receptor 1Homo sapiens (human)Kd0.00030.00030.00030.0003AID622092
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
immune responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
activation of adenylate cyclase activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
female pregnancyCorticotropin-releasing factor receptor 1Homo sapiens (human)
parturitionCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adrenal gland developmentCorticotropin-releasing factor receptor 1Homo sapiens (human)
exploration behaviorCorticotropin-releasing factor receptor 1Homo sapiens (human)
fear responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
behavioral response to ethanolCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
general adaptation syndrome, behavioral processCorticotropin-releasing factor receptor 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 1Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of corticosterone secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
neuron projectionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (39)

Assay IDTitleYearJournalArticle
AID248932Inhibition of CRF stimulated cAMP production in CHO cells expressing CRF1 receptor2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
AID26341pKa value was determined2003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.
AID1293590Ex vivo inhibition of [125I]-CRF binding to CRF1 receptor in mouse pituitary gland at 20 mg/kg, po after 1 hr by gamma scintillation counting method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
AID622045Antagonist activity at recombinant human CRF1 receptor expressed in CHO cells assessed as inhibition of CRF-induced cAMP formation2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID622093Antagonist activity at recombinant human CRF1 receptor expressed in CHO cells assessed as suppression on CRF1-induced maximum response by Schild analysis assay2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID622092Binding affinity to recombinant human CRF1 receptor expressed in CHO cells2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID608104Decrease in restrained-stress induced ATCH release in plasma of Sprague-Dawley rat at 3 mg/kg, po pretreated with compound for 1 hr by radioimmunoassay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID607641Ex vivo CRF-1 receptor occupancy in po dosed rat cortical homogenate assessed as inhibition of [I125]-sauvagine binding pretreated for 3 hrs2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID608106Antihyperlocomotion activity in Wistar rat assessed as decrease in CRF-induced hyperlocomotion at 3 mg/kg, po administered 1 hr before CRF challenge measured after 1 hr2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID236171Plasma clearance determined in dawley rats2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
AID1253854Displacement of [125I]-Tyr0-sauvagine from human CRF1 receptor expressed in HEK293T cells after 2 hrs by scintillation counting2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) rec
AID1435128Displacement of ovine [125-I]-CRF from human CRF1 receptor expressed in CHO cell membranes preincubated for 1 hr followed by compound washout for 2 hrs and subsequent addition of [125I]-CRF measured after 1 hr by liquid scintillation counting method
AID622091Antagonist activity at recombinant human CRF1 receptor expressed in CHO cells assessed as dissociation half life2011Bioorganic & medicinal chemistry letters, Oct-15, Volume: 21, Issue:20
Discovery of potent, metabolically stable purine CRF-1 antagonists with differentiated binding kinetic profiles.
AID608105Antihyperlocomotion activity in Wistar rat assessed as decrease in CRF-induced hyperlocomotion at 10 mg/kg, po administered 1 hr before CRF challenge measured after 1 hr2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID1293579Displacement of [125I]-CRF from human CRF1 receptor expressed in CHO cellular membrane fraction after 1.5 hrs by liquid scintillation counting method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
AID53978Displacement of [125I]-sauvagine from Corticotropin releasing factor receptor 1 endogenously expressed in IMR-32 human neuroblastoma cells2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
3-Aryl pyrazolo[4,3-d]pyrimidine derivatives: Nonpeptide CRF-1 antagonists.
AID1253856Displacement of [125I]-Tyr0-sauvagine from CRF1 receptor (unknown origin)2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) rec
AID1293586Ex vivo inhibition of [125I]-CRF binding to CRF1 receptor in mouse frontal cortex at 20 mg/kg, po after 1 hr by gamma scintillation counting method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
AID236286Plasma volume distribution determined in dawley rats2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
AID239538Inhibition of [125I]sauvagine binding to corticotropin releasing factor receptor 1 expressed in LtK- cells2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
AID237115Plasma half-life determined in dawley rats2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
AID1435127Displacement of ovine [125-I]-CRF from human CRF1 receptor expressed in CHO cell membranes preincubated for 1 hr followed by [125I]-CRF addition measured after 1 hr by liquid scintillation counting method
AID538004Antagonist activity at human recombinant CRF1 receptor2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
AID239431Inhibition of [125I]o-CRF binding to CHO cells expressing human CRF1 receptor2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
AID1253855Displacement of [125I]-antisauvagine-30 from human CRF2 receptor expressed in HEK293T cells at 1 uM after 2 hrs by scintillation counting2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) rec
AID1293580Cytotoxicity against human HepG2 cells assessed as rate of ATP content at 30 uM after 1 day by ATPLite-M assay relative to control2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
AID1435129Ratio of IC50 for displacement of ovine [125-I]-CRF from human CRF1 receptor expressed in CHO cell membranes with compound washout to IC50 for displacement of ovine [125-I]-CRF from human CRF1 receptor expressed in CHO cell membranes without compound wash
AID1293588Ex vivo inhibition of [125I]-CRF binding to CRF1 receptor in mouse olfactory bulb at 20 mg/kg, po after 1 hr by gamma scintillation counting method2016Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6
Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
AID683206Antagonist activity at human CRF1 receptor expressed in IMR32 cells assessed as inhibition of CRF-stimulated cAMP accumulation2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.
AID608155Displacement of [125I]-sauvagine from rat CRF-1 receptor expressed in rat cortical membrane after 2 hrs by scintillation counting2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID608103Decrease in restrained-stress induced ATCH release in plasma of Sprague-Dawley rat at 10 mg/kg, po pretreated with compound for 1 hr by radioimmunoassay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID362068Displacement of [125I]sauvagine from human CRF1 receptor expressed in IMR32 cells2008Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16
2-Arylpyrimidines: novel CRF-1 receptor antagonists.
AID609182Antagonist activity at human CRF-1 receptor2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist.
AID346894Displacement of [125I]sauvagine from human recombinant CRF1 receptor expressed in CHO cells2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Synthesis and pharmacological characterization of novel druglike corticotropin-releasing factor 1 antagonists.
AID242269Inhibition of [125I]o-CRF binding to CHO cells expressing human CRF1 receptor2004Journal of medicinal chemistry, Sep-09, Volume: 47, Issue:19
Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
AID21716Solubility at pH 42003Bioorganic & medicinal chemistry letters, Oct-06, Volume: 13, Issue:19
Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factor1 (CRF1) receptor antagonists.
AID538005Metabolic stability in human liver microsome assessed as maximum bioavailability2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
AID705772Antagonist activity at CRF1 receptor in human IMR32 cells assessed as inhibition of CRF-induced intracellular cAMP accumulation after 30 mins by immunoassay2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
AID1345736Human CRF1 receptor (Corticotropin-releasing factor receptors)
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (78)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's42 (53.85)29.6817
2010's34 (43.59)24.3611
2020's2 (2.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.96 (24.57)
Research Supply Index4.48 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (4.82%)5.53%
Reviews6 (7.23%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other73 (87.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]